Iambic Therapeutics

Breakthrough AI-driven drug discovery.

About

Founded

2019

Headquarters

La Jolla, California

Industry

Artificial Intelligence (AI)

Company Description

Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinic with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs.

Quick Links

WebsiteJobs

Funding

Total Raised

$153 million

Valuation

Undisclosed

Significant Investors

Sequoia Capital, Coatue, Catalio Capital Management, Nexus Ventures, Freeflow

Company Traction

  • Iambic Therapeutics claims Orbnet, its AI-drive drug development process, can create a thousand-fold acceleration in molecular properties prediction with 100x less training data required.
  • As of May 2023, Iambic Therapeutics is working on the company’s first clinical candidate, ENT-H1.
  • As of May 2023, Iambic Therapeutics has four indications in its pipeline: Effector protein; Non-kinase target; Challenging kinase selectivity profile; HER2, including oncogenic mutations.

Leadership Team

  • Thomas Miller: Co-Founder & CEO of Iambic Therapeutics. Former Professor of Chemistry at California Institute of Technology.
  • Fred Manby: Co-Founder & CTO of Iambic Therapeutics. Former Co-Director of Theory and Modelling in Chemical Sciences.
  • Tim Cernak: Co-Founder & Chief Scientific Officer of Iambic Therapeutics. Former Associate Principal Scientist at Merck.
  • Chao Zhang: Chief Scientific Officer at Iambic Therapeutics. Former CEO at Plexxikon.
  • Mary Anderson: SVP of Business Development at Iambic Therapeutics. Former VP of Business Development at Turning Point Therapeutics.

Press

  • Iambic Therapeutics (October 3, 2023): Series B